CA2429162C - Methods and compositions for enhancing cellular function through protection of tissue components - Google Patents
Methods and compositions for enhancing cellular function through protection of tissue components Download PDFInfo
- Publication number
- CA2429162C CA2429162C CA002429162A CA2429162A CA2429162C CA 2429162 C CA2429162 C CA 2429162C CA 002429162 A CA002429162 A CA 002429162A CA 2429162 A CA2429162 A CA 2429162A CA 2429162 C CA2429162 C CA 2429162C
- Authority
- CA
- Canada
- Prior art keywords
- machr
- pyrophosphate
- receptor
- glycerol
- agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
- A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20084300P | 2000-05-01 | 2000-05-01 | |
US60/200,843 | 2000-05-01 | ||
US23026300P | 2000-09-06 | 2000-09-06 | |
US60/230,263 | 2000-09-06 | ||
US23302500P | 2000-09-15 | 2000-09-15 | |
US60/233,025 | 2000-09-15 | ||
PCT/US2001/013931 WO2001082932A2 (en) | 2000-05-01 | 2001-04-30 | Methods and compositions for enhancing cellular function through protection of tissue components |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2429162A1 CA2429162A1 (en) | 2001-11-08 |
CA2429162C true CA2429162C (en) | 2010-01-05 |
Family
ID=27394213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002429162A Expired - Fee Related CA2429162C (en) | 2000-05-01 | 2001-04-30 | Methods and compositions for enhancing cellular function through protection of tissue components |
Country Status (7)
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6902881B2 (en) | 2000-10-13 | 2005-06-07 | President And Fellows Of Harvard College | Compounds and methods for regulating cell differentiation |
US6908732B2 (en) | 2000-10-13 | 2005-06-21 | President & Fellows Of Harvard College | Compounds and methods for regulating cell differentiation |
EP1404318A2 (en) * | 2000-11-10 | 2004-04-07 | The President and Fellows of Harvard College | Compounds and methods for regulating cell differentiation |
CA2347330C (en) * | 2001-05-10 | 2002-03-12 | Pharmaceutical Partners Of Canada Inc. | Liquid injectable formulation of disodium pamidronate |
FR2828206B1 (fr) * | 2001-08-03 | 2004-09-24 | Centre Nat Rech Scient | Utilisation d'inhibiteurs des lysyl oxydases pour la culture cellulaire et le genie tissulaire |
US20140212508A1 (en) * | 2001-12-20 | 2014-07-31 | John Wayne Kennedy | Copper/zinc superoxide dismutase (sod) formulation for the treatment of traumas including amyotropic lateral sclerosis |
WO2003092700A1 (en) | 2002-04-29 | 2003-11-13 | Gmp Oxycell, Inc. | Inositol pyrophosphates, and methods of use thereof |
US20040127409A1 (en) * | 2002-11-07 | 2004-07-01 | Milkhaus Laboratory, Inc. | Method of treatment of psychological conditions by administration of nerve growth factor |
US8367610B2 (en) * | 2002-11-07 | 2013-02-05 | Beech Tree Labs, Inc. | Method of treating cravings by administration of nerve growth factor |
AU2003300012A1 (en) * | 2002-12-30 | 2004-07-29 | Indiana University Research & Technology Corporation | Method of treatment for central nervous system injury |
EP1631315B1 (en) | 2003-09-24 | 2014-07-30 | Millennium Pharmaceuticals, Inc. | Antibodies which bind human cxcr3 |
US20080045500A1 (en) * | 2004-07-01 | 2008-02-21 | Eisai R&D Management Co., Ltd. | Nerve Regeneration Stimulator |
US20060258626A1 (en) * | 2004-07-06 | 2006-11-16 | Claude Nicolau | Use of inositol-tripyrophosphate in treating tumors and diseases |
US20060106000A1 (en) * | 2004-07-06 | 2006-05-18 | Claude Nicolau | Use of inositol-tripyrophosphate in treating tumors and diseases |
US7745423B2 (en) * | 2004-07-06 | 2010-06-29 | NormOxys, Inc | Calcium/sodium salt of inositol tripyrophosphate as an allosteric effector of hemoglobin |
US7618615B2 (en) | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
US9216161B2 (en) | 2004-08-13 | 2015-12-22 | Healthpartners Research Foundation | Methods of treating Huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity |
GB0502250D0 (en) * | 2005-02-03 | 2005-03-09 | Ic Vec Ltd | Use |
DK1863495T3 (en) * | 2005-03-18 | 2015-04-20 | Normoxys Inc | CALCIUM AND SODIUM SALT OF MYO-INOSITOL 1.6: 2,3: 4,5 TRIPYROPHOSPHATE FOR CANCER TREATMENT |
US20070032443A1 (en) * | 2005-08-02 | 2007-02-08 | Jaeseob Kim | Therapy for Alzheimer's disease |
EP1928484B1 (en) | 2005-08-26 | 2010-02-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for treatment of headaches by administration of oxytocin |
EP2005171B1 (en) * | 2006-03-23 | 2012-08-08 | The General Hospital Corporation | Inflammation-inhibitory serum factors and uses thereof |
WO2008019431A1 (en) * | 2006-08-14 | 2008-02-21 | Brc Operations Pty Limited | Method and compositions for simultaneously regulating memory and mood |
JP2010526068A (ja) * | 2007-05-01 | 2010-07-29 | ノームオクシス インコーポレイテッド | エリスロポエチン補完または置換 |
US9707274B2 (en) | 2007-06-08 | 2017-07-18 | Healthpartners Research & Education | Methods for preventing and treating post-traumatic stress disorder (PTSD) |
AU2008282273A1 (en) * | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Pyrone analog compositions and methods |
US7947733B2 (en) * | 2007-07-31 | 2011-05-24 | Limerick Biopharma | Phosphorylated pyrone analogs and methods |
US20100249073A1 (en) * | 2009-03-27 | 2010-09-30 | Robert Sabin | Prophylactic and therapeutic treatment of Alzheimer's disease using phytic acid and phytate to reduce amyloid beta plaque and tau protein |
US20110091440A1 (en) * | 2009-03-27 | 2011-04-21 | Robert Sabin | Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases |
PL3061821T3 (pl) | 2009-07-22 | 2020-01-31 | PureTech Health LLC | Kompozycje do leczenia zaburzeń łagodzonych przez aktywację receptora muskarynowego |
US10265311B2 (en) | 2009-07-22 | 2019-04-23 | PureTech Health LLC | Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation |
WO2011119136A1 (en) * | 2010-03-26 | 2011-09-29 | Robert Sabin | Prophylactic and therapeutic treatment of neuro-degenerative diseases and protein aggregation diseases |
US8609088B2 (en) | 2011-05-10 | 2013-12-17 | Regents Of The University Of Minnesota | Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases |
WO2012174481A1 (en) | 2011-06-15 | 2012-12-20 | Nerve Access, Inc. | Pharmaceutical compositions for intranasal administration for the treatment of neurodegenerative disorders |
US10279012B2 (en) | 2013-03-11 | 2019-05-07 | Healthpartners Research & Education | Methods of treating and preventing social communication disorder in patients by intranasal administration of insulin |
CN115120746A (zh) | 2013-05-15 | 2022-09-30 | 明尼苏达大学董事会 | 腺相关病毒介导的基因向中枢神经系统转移 |
US10314911B2 (en) | 2014-04-08 | 2019-06-11 | Healthpartners Research & Education | Methods for protecting and treating traumatic brain injury, concussion and brain inflammation with intranasal insulin |
NZ725921A (en) | 2014-04-23 | 2023-09-29 | Takeda Pharmaceuticals Co | Isoindoline-1-one derivatives as cholinergic muscarinic m1 receptor positive alloesteric modulator activity for the treatment of alzheimers disease |
CA3111682A1 (en) | 2014-06-26 | 2015-12-30 | Island Breeze Systems Ca, Llc | Mdi related products and methods of use |
KR20180023884A (ko) | 2015-01-07 | 2018-03-07 | 트라이제미나 인코퍼레이티드 | 마그네슘-함유 옥시토신 제제 및 사용 방법 |
AU2016284654B9 (en) | 2015-06-26 | 2020-05-21 | Takeda Pharmaceutical Company Limited | 2,3-dihydro-4h-1,3-benzoxazin-4-one derivatives as modulators of cholinergic muscarinic M1 receptor |
WO2017069173A1 (ja) | 2015-10-20 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
JP7171439B2 (ja) | 2016-04-15 | 2022-11-15 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ムコ多糖症ii型を処置するための遺伝子療法 |
US10471007B2 (en) | 2016-12-16 | 2019-11-12 | Jeffrey R Olynyk | Sublingual therapeutic solutions and methods |
PE20200017A1 (es) | 2017-06-01 | 2020-01-06 | Lilly Co Eli | Composiciones de insulina de rapida accion |
CN111163783A (zh) * | 2017-08-08 | 2020-05-15 | 美国政府卫生与公众服务部 | 抑制hiv-1逆转录酶的组合物和方法 |
US11819539B2 (en) | 2017-09-22 | 2023-11-21 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating Mucopolysaccharidosis type II |
BR112021005802B1 (pt) | 2018-09-28 | 2022-02-15 | Karuna Therapeutics, Inc | Composição farmacêutica oral |
US11676198B2 (en) | 2019-07-30 | 2023-06-13 | Skipify, Inc. | Computer-implemented methods of completing an online transaction that is performed via a user computing device and a merchant website running on a merchant computing device |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023248A (en) * | 1984-10-23 | 1991-06-11 | Perstorp Ab | Method of treating diabetes with inositol triphosphate |
JPS61263902A (ja) | 1985-05-16 | 1986-11-21 | Rikagaku Kenkyusho | 植物病害防除剤 |
US5135923A (en) * | 1986-04-16 | 1992-08-04 | Perstorp Ab | Method of treating cardiovascular diseases |
FR2629716B1 (fr) * | 1988-04-07 | 1991-07-19 | Sanofi Sa | Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique |
US5082833A (en) | 1988-06-30 | 1992-01-21 | Shamsuddin Abulkalam M | Reduction of cell proliferation and enhancement of nk-cell activity |
DE69031279T2 (de) * | 1989-12-05 | 1998-03-19 | Ramsey Foundation | Neurologische wirkstoffe zur nasalen verabreichung an das gehirn |
US5132923A (en) * | 1990-02-23 | 1992-07-21 | J.A. King & Company, Inc. | System for monitoring storage tanks |
US5652227A (en) * | 1995-01-30 | 1997-07-29 | Teronen; Olli Pekka | Inhibition of the degradation of connective tissue matrix protein components in mammals |
WO1996039150A1 (en) * | 1995-06-06 | 1996-12-12 | Merck & Co., Inc. | Bisphosphonate therapy for bone loss associated with rheumatoid arthritis |
US5939395A (en) * | 1995-06-07 | 1999-08-17 | Board Of Regents, The University Of Texas System | Identification of a potent antioxidant from Aloe barbadensis |
US5874573A (en) * | 1995-06-26 | 1999-02-23 | Concat, Inc. | Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy |
US6083920A (en) | 1995-12-21 | 2000-07-04 | Ayurcore, Inc. | Compositions for modulating intracellular inositol trisphosphate concentration |
EP1027045A4 (en) * | 1997-10-31 | 2004-12-08 | Arch Dev Corp | METHODS AND COMPOSITIONS FOR REGULATING 5-ALPHA-REDUCTASE ACTIVITY |
US7618615B2 (en) * | 2004-08-13 | 2009-11-17 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against neurodegeneration caused by ischemia |
-
2001
- 2001-04-27 US US09/844,450 patent/US7084126B1/en not_active Expired - Fee Related
- 2001-04-30 AU AU2001257444A patent/AU2001257444A1/en not_active Abandoned
- 2001-04-30 CA CA002429162A patent/CA2429162C/en not_active Expired - Fee Related
- 2001-04-30 WO PCT/US2001/013931 patent/WO2001082932A2/en active IP Right Grant
- 2001-04-30 DE DE60124240T patent/DE60124240T2/de not_active Expired - Lifetime
- 2001-04-30 AT AT01930957T patent/ATE344040T1/de not_active IP Right Cessation
- 2001-04-30 EP EP01930957A patent/EP1278525B1/en not_active Expired - Lifetime
-
2005
- 2005-07-28 US US11/191,901 patent/US7972595B2/en not_active Expired - Fee Related
- 2005-09-06 US US11/220,223 patent/US8771681B2/en not_active Expired - Fee Related
- 2005-09-06 US US11/220,222 patent/US9072756B2/en not_active Expired - Fee Related
- 2005-09-06 US US11/220,116 patent/US7786166B2/en not_active Expired - Fee Related
- 2005-09-06 US US11/220,115 patent/US8772263B2/en not_active Expired - Fee Related
-
2011
- 2011-05-17 US US13/109,756 patent/US8765711B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
DE60124240T2 (de) | 2007-06-28 |
US20060030542A1 (en) | 2006-02-09 |
US7084126B1 (en) | 2006-08-01 |
WO2001082932A2 (en) | 2001-11-08 |
CA2429162A1 (en) | 2001-11-08 |
US20020028786A1 (en) | 2002-03-07 |
EP1278525A2 (en) | 2003-01-29 |
AU2001257444A1 (en) | 2001-11-12 |
US8765711B2 (en) | 2014-07-01 |
US7786166B2 (en) | 2010-08-31 |
US20060009414A1 (en) | 2006-01-12 |
US20060009413A1 (en) | 2006-01-12 |
US8771681B2 (en) | 2014-07-08 |
EP1278525B1 (en) | 2006-11-02 |
US20050272642A1 (en) | 2005-12-08 |
US7972595B2 (en) | 2011-07-05 |
US20060014716A1 (en) | 2006-01-19 |
US9072756B2 (en) | 2015-07-07 |
ATE344040T1 (de) | 2006-11-15 |
US20110236365A1 (en) | 2011-09-29 |
WO2001082932A3 (en) | 2002-07-18 |
US8772263B2 (en) | 2014-07-08 |
DE60124240D1 (de) | 2006-12-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2429162C (en) | Methods and compositions for enhancing cellular function through protection of tissue components | |
Duan et al. | Protection and treatment of sensorineural hearing disorders caused by exogenous factors: experimental findings and potential clinical application | |
EP1864667B1 (en) | Use of prodrugs for ocular intravitreous administration | |
SK154796A3 (en) | Use of rapamycin for the inhibition of neuronal cells necrosis | |
UA127738C2 (uk) | Проліки дантролену і способи їх застосування | |
US20100160367A1 (en) | Pharmaceutical compositions containing pyrroloquinoline quinone and nephroprotectant for treating ischemia reperfusion injuries | |
EP1558256B1 (en) | Pyrroloquinoline quinone and a beta blocker for the treatment of ischemia or reperfusion injury | |
MXPA02004871A (es) | Combinaciones farmaceuticas. | |
EP3102216A1 (en) | Formulations for microparticle delivery of zinc protoporphyrins | |
US20110171134A1 (en) | (6s)-5-methyltetrahydrofolic acid for therapy of tissue injury | |
Loeb et al. | Liposome‐entrapped GABA modifies behavioral and electrographic changes of penicillin‐induced epileptic activity | |
JP2018062537A (ja) | 化学療法誘発認知障害の処置 | |
US20220000889A1 (en) | Inositol phosphate compounds for use in increasing tissular perfusion | |
CA2565616A1 (en) | Pyrroloquinoline quinone drugs for treatment of cardiac injury | |
US20230241231A1 (en) | Central nervous system delivery of psilocybin | |
JP2004504346A (ja) | 骨転移の治療におけるリン酸エストラムスチンの使用 | |
EP3678702A1 (en) | Treatment of neurodegenerative diseases | |
EP4125816A1 (en) | Materials and methods for immunosuppressive tumor microenvironment-targeted cancer therapy | |
CA2664251A1 (en) | Isovaline for treatment of pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20180430 |